Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07298135

A Study to Evaluate the Effects of a Prebiotic Soda on Glycemic Control in Adults

The main objective of this study is to evaluate the chronic effects of replacing traditional non-diet soda with a prebiotic soda on biomarkers associated with glycemic control in adults with glucose dysregulation who are habitual consumers of traditional soda.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

People Science

Los Angeles, California, 90045, United States

Location status: Recruiting

Location contact

People Science

CONTACT

[email protected]

About this study

The primary aim of this clinical trial is to evaluate the effects of replacing traditional non-diet soda with a prebiotic soda (i.e., OLIPOP) over an 8 week period on markers of glucose (blood sugar) control in adults with glucose (blood sugar) dysregulation.

Participants (n=224) will be habitual consumers of traditional non-diet sodas, consuming on average 2-3 servings of non-diet soda daily. Participants will be randomized to either an active control group (continued habitual traditional non-diet soda intake, 2 - 3 servings/day) or a behavioral intervention group (OLIPOP prebiotic soda, 2 cans/day (24 fl. oz/day), 6 g dietary fiber and 2 - 5 g total sugar per 12 fl. oz can).

Secondary outcomes will include evaluating the effects of prebiotic soda consumption on additional markers of metabolic health, including long-term glycemic control and insulin sensitivity.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to provide informed consent
  • Willing to comply with all study procedures
  • Male or female, ages 30 - 70 years old
  • Habitual consumers of traditional non-diet soda (average intake 2 - 3 servings (24-36 fl. oz)/daily in a typical month, representing usual dietary pattern)
  • BMI between 25 - 35 kg/m²
  • Fasting plasma glucose between 100 - 125 mg/dL or hemoglobin A1c between 5.7% - 6.4%
  • Low habitual dietary fiber intake, assessed using a qualitative fiber intake screening questionnaire administered at pre-screening
  • Willing to maintain stable tobacco/nicotine use habits established for ≥ 90 days, with no initiation, cessation, or change in frequency during the study period
  • Willing to maintain stable marijuana, hemp, and CBD product use habits established for ≥ 60 days, with no initiation, cessation, or change in frequency during the study period
  • Willing to maintain habitual diet (with the exception of study products) and physical activity patterns throughout the trial

Exclusion criteria

  • Inability to consume a standard 12 fl. oz. carbonated beverage twice daily
  • Currently engaged or planning to be on an intensive weight loss regimen program
  • Extreme dietary habits in the judgement of the Investigator or has been diagnosed with an eating disorder
  • Habitual use of fiber supplements, inulin-based supplements, acacia fiber, glucomannan, prebiotic supplements, or probiotic supplements within 30 days of study enrollment
  • Known allergy or sensitivity to any of the ingredients in the study products
  • History or presence of uncontrolled and/or clinically important medical conditions that could interfere with study results interpretation (i.e., diabetes mellitus, CKD stage 4-5, severe liver disease/cirrhosis, uncontrolled hypertension, recent myocardial infarction or stroke (within 6 months), severe mental illness or cognitive impairment, immunodeficiency disorders, active infections).
  • Gastrointestinal conditions that could potentially interfere with absorption of the study product (i.e., IBD, celiac disease, short bowel syndrome, chronic pancreatitis, gastroparesis, active peptic ulcer disease, gastric bypass or other bariatric surgeries, severe IBS, chronic diarrhea or malabsorption syndromes, active diverticulitis)
  • Use of oral or injectable steroids within 90 days of enrollment
  • Use of antibiotic therapy within 90 days of enrollment
  • Unstable use of prescription medications within 90 days of enrollment that affect plasma glucose levels (e.g., corticosteroids, thiazide diuretics, beta-blockers (some types), antipsychotics, tacrolimus, protease inhibitors, ACE inhibitors)
  • Use of any of the following prescription medications within 90 days of enrollment: Metformin, sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors, insulin.
  • History or presence of cancer, except non-melanoma skin cancer, within 2 years of enrollment
  • Exposure to any non-registered drug product or participation in another intervention study within 30 days prior to enrollment
  • Recent history (within 12 months) of alcohol or substance abuse
  • History of major trauma or surgical event within 60 days of enrollment
  • Person who is pregnant, planning pregnancy, or lactating
  • Any condition the Investigator believes would interfere with study participation or compliance
  • Consumption of more than 5 prebiotic sodas within the last 30 days prior to enrollment
  • Heavy smoker as defined as smoking 20 or more cigarettes per day, or smoked roughly 1 pack a day for 20+ years (more than 20 pack years)

Treatment and study plan

Prebiotic Soda

Behavioral

Participants will replace traditional non-diet sodas in their diet with a prebiotic soda (OLIPOP). Participants will consume 2 cans/day (24 fl. oz/day) that will add 12 g dietary fiber/day to their diet.

Active Control

Behavioral

Participants will continue to consume their habitual intake (on average 2-3 servings/day) of traditional non-diet soda.

Primary outcomes

  1. Effects on Fasting Plasma Glucose

    Time frame: Baseline to 8 weeks

    Change in fasting plasma glucose

Secondary outcomes

  1. Effects on Long-term Glycemic Control

    Time frame: Baseline to week 8

    Change in HbA1c

  2. Effect on insulin sensitivity

    Time frame: Baseline to week 8

    Change in fasting plasma insulin

Study contacts

Contact information is provided by the study sponsor or research team.

Megha Doshi

CONTACT

[email protected]

People Science

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Olipop, PBC

Industry

Collaborators

  • People Science

Registry information

Official study title

A Randomized, Open-Label, Controlled Study to Evaluate the Effects of a Prebiotic Soda on Glycemic Control in Adults With Glucose Dysregulation

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 23, 2025
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.